Pub Date : 2019-01-01DOI: 10.17925/eoh.2019.15.2.102
Yhasmine Delles Oliverira Garcia, Juliene Lima Mesquita, Y. Z. Rosales, T. Santos, A. G. Moura, João Vitor Araújo Duarte, Beatrice Araújo Duarte, E. Velloso, F. D. R. Filho, F. Duarte, R. Lemes
{"title":"Isochromosome i(7)(q10) in Myelodysplastic Syndrome – Case Report","authors":"Yhasmine Delles Oliverira Garcia, Juliene Lima Mesquita, Y. Z. Rosales, T. Santos, A. G. Moura, João Vitor Araújo Duarte, Beatrice Araújo Duarte, E. Velloso, F. D. R. Filho, F. Duarte, R. Lemes","doi":"10.17925/eoh.2019.15.2.102","DOIUrl":"https://doi.org/10.17925/eoh.2019.15.2.102","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67593133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.17925/eoh.2019.15.2.86
Y. Wu
{"title":"Targeting Tyrosine-protein Kinase Receptor (MET) Gene Alterations in Non-small Cell Lung Cancer – The Efficacy and Safety of Tepotinib + Gefitinib in the INSIGHT Study","authors":"Y. Wu","doi":"10.17925/eoh.2019.15.2.86","DOIUrl":"https://doi.org/10.17925/eoh.2019.15.2.86","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.17925/eoh.2019.15.1.14
M. Cappellini
{"title":"Gaucher Disease for the Haematologist","authors":"M. Cappellini","doi":"10.17925/eoh.2019.15.1.14","DOIUrl":"https://doi.org/10.17925/eoh.2019.15.1.14","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.17925/eoh.2019.15.2.1
B. Maughan, J. Gschwend
{"title":"Treatment Sequencing of Abiraterone Acetate plus Prednisone and Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer","authors":"B. Maughan, J. Gschwend","doi":"10.17925/eoh.2019.15.2.1","DOIUrl":"https://doi.org/10.17925/eoh.2019.15.2.1","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67593095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.17925/eoh.2019.15.1.16
J. Muñoz
{"title":"Chimeric Antigen Receptor T-cell Therapy for Relapsed or Refractory Large B-cell Lymphoma – Latest Data from the ZUMA-1 Study","authors":"J. Muñoz","doi":"10.17925/eoh.2019.15.1.16","DOIUrl":"https://doi.org/10.17925/eoh.2019.15.1.16","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67593021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.17925/eoh.2019.15.1.53
T. Vassilakopoulos, B. Böll
Hodgkin lymphoma is a B-cell lymphoma that currently has a cure rate of ≥85% in patients with early-stage disease, using first-line chemotherapy followed by involved field radiotherapy. However, an unmet need remains in those with advanced and relapsed/ refractory Hodgkin lymphoma. In this review, we provide an overview of new and developing agents and discuss how these may re-shape clinical care strategies for patients with Hodgkin lymphoma. Overall, the emergence of targeted therapies such as brentuximab vedotin and immunotherapies such as nivolumab or pembrolizumab, provide new and exciting treatment options for patients. It is hoped that these will form single-agent and combination strategies that will re-shape the therapeutic landscape in Hodgkin lymphoma by (i) replacing elements of standard chemotherapy in low-risk patients to reduce toxicity and long-term complications, and (ii) by integrating into standardof-care therapies for advanced, high-risk or relapsed patients. Currently, brentuximab vedotin provides more robust and mature phase III clinical data in Hodgkin lymphoma, based on which, it appears reasonable to predict that brentuximab vedotin will form part of the first-line therapy for advanced Hodgkin lymphoma.
{"title":"Treatment of Hodgkin Lymphoma – New and Developing Therapies and Their Potential Role in Standard of Care","authors":"T. Vassilakopoulos, B. Böll","doi":"10.17925/eoh.2019.15.1.53","DOIUrl":"https://doi.org/10.17925/eoh.2019.15.1.53","url":null,"abstract":"Hodgkin lymphoma is a B-cell lymphoma that currently has a cure rate of ≥85% in patients with early-stage disease, using first-line chemotherapy followed by involved field radiotherapy. However, an unmet need remains in those with advanced and relapsed/ refractory Hodgkin lymphoma. In this review, we provide an overview of new and developing agents and discuss how these may re-shape clinical care strategies for patients with Hodgkin lymphoma. Overall, the emergence of targeted therapies such as brentuximab vedotin and immunotherapies such as nivolumab or pembrolizumab, provide new and exciting treatment options for patients. It is hoped that these will form single-agent and combination strategies that will re-shape the therapeutic landscape in Hodgkin lymphoma by (i) replacing elements of standard chemotherapy in low-risk patients to reduce toxicity and long-term complications, and (ii) by integrating into standardof-care therapies for advanced, high-risk or relapsed patients. Currently, brentuximab vedotin provides more robust and mature phase III clinical data in Hodgkin lymphoma, based on which, it appears reasonable to predict that brentuximab vedotin will form part of the first-line therapy for advanced Hodgkin lymphoma.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"287 1","pages":"53"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72749184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.17925/eoh.2019.15.1.22
M. Lozano, J. Cid, D. Benítez-Ribas, M. Otero
{"title":"Technical Challenges in the Manufacture of Dendritic Cell Cancer Therapies","authors":"M. Lozano, J. Cid, D. Benítez-Ribas, M. Otero","doi":"10.17925/eoh.2019.15.1.22","DOIUrl":"https://doi.org/10.17925/eoh.2019.15.1.22","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67593037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.17925/eoh.2019.15.2.113
Wesley Messias Santos, A. F. Costa, L. H. S. Pinheiro, N. L. Silva, A. Sandes, M. A. Nunes, C. Corrêa, Carlos Arthur Cardoso Almeida, G.M.S. Cruz, D. L. Junior, D. M. Schimieguel
{"title":"Role of New Immunophenotypic Markers on Prognostic and Overall Survival of Acute Lymphoblastic Leukaemia – A Systematic Review and Meta-analysis","authors":"Wesley Messias Santos, A. F. Costa, L. H. S. Pinheiro, N. L. Silva, A. Sandes, M. A. Nunes, C. Corrêa, Carlos Arthur Cardoso Almeida, G.M.S. Cruz, D. L. Junior, D. M. Schimieguel","doi":"10.17925/eoh.2019.15.2.113","DOIUrl":"https://doi.org/10.17925/eoh.2019.15.2.113","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67593174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：